Treatment of severe refractory uveitis with intravenous cyclophosphamide

J. T. Rosenbaum

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Objective. We assessed the efficacy of intravenous (iv) cyclophosphamide therapy for patients with uveitis. Methods. Eleven patients with uveitis were treated with iv cyclophosphamide. Patients were from a tertiary care, referral practice, had failed oral corticosteroid therapy, and had disease that interfered with activities of daily living. Results. Only 5 patients benefitted and the improvement was sustained without additional immunosuppression in only 2 patients, one of whom had only mild eye disease and was receiving cyclophosphamide for a central nervous system vasculitis. Four patients worsened during the therapy. Conclusion. Although iv cyclophosphamide may have fewer risks than daily, oral cyclophosphamide, the majority of patients with uveitis do not experience a sustained benefit from this therapeutic approach.

Original languageEnglish (US)
Pages (from-to)123-125
Number of pages3
JournalJournal of Rheumatology
Issue number1
StatePublished - 1994
Externally publishedYes


  • cyclophosphamide
  • immunosuppression
  • uveitis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Treatment of severe refractory uveitis with intravenous cyclophosphamide'. Together they form a unique fingerprint.

Cite this